|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价NWRD06在肝细胞癌根治术后患者中的安全性和免疫原性的I期临床研究
[Translation] Phase I clinical study to evaluate the safety and immunogenicity of NWRD06 in patients after radical resection of hepatocellular carcinoma
主要目的:评价NWRD06裸质粒DNA注射液在肝细胞癌根治术后患者中的安全性、耐受性,探索NWRD06的最大耐受剂量(MTD)及II期推荐剂量(RP2D)。
次要目的:评价NWRD06裸质粒DNA注射液在肝细胞癌根治术后患者中的免疫原性。
[Translation] Main purpose: To evaluate the safety and tolerability of NWRD06 naked plasmid DNA injection in patients after radical resection of hepatocellular carcinoma, and to explore the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of NWRD06.
Secondary purpose: To evaluate the immunogenicity of NWRD06 naked plasmid DNA injection in patients after radical resection of hepatocellular carcinoma.
100 Clinical Results associated with Newish Technology (Taizhou) Co., Ltd.
0 Patents (Medical) associated with Newish Technology (Taizhou) Co., Ltd.
100 Deals associated with Newish Technology (Taizhou) Co., Ltd.
100 Translational Medicine associated with Newish Technology (Taizhou) Co., Ltd.